Acute Myeloid Leukemia: Cytarabine Here to Stay - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1026

Acute Myeloid Leukemia: Cytarabine Here to Stay

Description:

Acute Myeloid Leukemia (AML) is an aggressive form of leukemia, mainly affecting the adult population, and within this subset, affecting males more than females. Approximately 23,000 individuals are expected to be diagnosed with AML over next year in the US, Japan and Europe. The likelihood of survival of AML patients is most easily defined by the genotype initiating the disease. The prognosis defined in this way can range from very poor to extended disease free survival in the most treatable cases. This brief provides an overview of the AML market, exploring the epidemiology and the most widely used treatment approaches. Subsequent sections of the brief examine the predicted evolution of the AML market with the release of some long awaited drugs and the future perspectives of the drug market.

Contents:

TABLE OF CONTENTS

EXECUTIVE SUMMARY

Disease overview

Acute Myeloid Leukemia

Epidemiology

Risk factors

DIAGNOSIS AND TREATMENT OF AML

Diagnosis and Staging

Treatment of AML

Overview

Stage specific breakdown of treatment

Remission therapy for AML

Currently approved drugs

Cytarabine

Daunorubicin

Idamycin (idarubicin)

Cost of AML treatment

UNMET NEEDS IN AML

AML PIPELINE

Gleevac (STI 571)

Proleukin (Aldesleukin)

Ceplene (Histamine dihydrochloride)

SMART HuM195

Troxatyl (troxacitabine)

Annamycin

DX-8951f

Irofulven

Others

Future incidence of AML

Trends in the cancer market to 2007

The niche cancer market

Market forecast for AML pipeline

References

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1026

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 13/10/2008 08:54:15

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com

Order information

Please verify that the product information is correct and select the format you require.


Product Name:
Acute Myeloid Leukemia: Cytarabine Here to Stay
Web Address:
http://www.researchandmarkets.com/reports/1026
Office Code:
OCHKGGIMOVX

Report formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Hard Copy		€1,669.00 + EUR€ 50.00 Shipping/Handling *
Electronic		€1,605.00
Electronic - Site License		€1,605.00

* Shipping/Handling is only charged once per order.

Contact information

Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Page 2 of 2
Printed 13/10/2008 08:54:15

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder Name:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World